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ABSTRACT

The safety, tolerability and pharmacokinetics of liposomal formulation of amphotericin B (L-AMB) were evaluated in 40 immunocompromised children and adolescents.  The protocol was an open-label, sequential-dose-escalation, multidose pharmacokinetic study with 10 to 13 patients in each of the four dosage cohorts.  Each cohort received daily dosages of 2.5, 5.0, 7.5 or 10 mg of amphotericin B in the form of L-AMB per kg of body weight. Neutropenic patients between ages 1 and 17 years were enrolled to receive empirical antifungal therapy or treatment of documented invasive fungal infections. The pharmacokinetic parameters of L-AMB were measured as those of amphotericin B by high-performance liquid chromatography and calculated by non-compartmental methods. There were nine adverse event-related discontinuations, four of which were related to infusions.  Infusion-related side effects occurred in 63 (11%) of 565 infusions with 5 patients experiencing acute infusion related reactions (7.5 and 10 mg/kg dosage levels). Serum creatinine increased from 0.45 ± 0.04 mg/dl to 0.63 ± 0.06 mg/dL in the overall population (p=0.003) with significant increases in dosage cohorts receiving 5.0 and 10 mg/kg/d.  At the higher dosage level of 10 mg/kg, there was a trend toward greater hypokalemia and vomiting.  The AUC0-24 values of L-AMB on day 1 increased from 54.7 ± 32.9 to 430 ± 566 µg•h/ml in patients receiving 2.5 and 10.0 mg/kg/day, respectively. These findings demonstrate that L-AMB can be administered to pediatric patients at dosages similar to those of adults and that azotemia may develop, especially in those receiving ≥ 5.0 mg/kg/d. 



INTRODUCTION

	Invasive fungal infections are important causes of morbidity and mortality in neutropenic pediatric patients [1-6].  Liposomal amphotericin B (L-AMB) has been used for prophylaxis, empirical antifungal therapy, and for treatment of documented mycoses in children and adults [7-15].   However, little is known about the pharmacokinetic properties of liposomal amphotericin B in pediatric patients [9,16].  To our knowledge, only one trial has reported the pharmacokinetics of multiple dosages of this compound in children [16].  We studied the safety, tolerability and pharmacokinetics of L-AMB in a sequential dose escalation, multi-dose pharmacokinetic study administered as empirical antifungal therapy in persistently febrile neutropenic pediatric patients.  

PATIENTS AND METHODS
Study design.  The objective of the study was to evaluate the safety, tolerability, and pharmacokinetics of intravenous L-AMB (AmBisome, Astellas Pharma USA, Inc., Deerfield, IL, USA) at four dosage levels in a population of immunocompromised pediatric patients, including those with cancer,  and progenitor (hematopoietic) stem cell transplantation (PSCT), HIV/AIDS, and other immunodeficiencies.  patients. Patients were eligible for study if (1) they were between the ages of 1 and 17 years, undergoing PSCT or receiving active chemotherapy for neoplastic disease; and (2) had persistent or recurrent fever (oral temperature  38.0° C) and neutropenia (absolute neutrophil count < 500/L) despite broad spectrum antibacterial therapy for five or more days, OR had culture or biopsy proven invasive fungal infection.  No forms of amphotericin B, other than study drug, were allowed during the study.  IRB approved informed consent was obtained from the patient or their legally authorized representative prior to their entry.
	Patients were not eligible for enrollment into study if (1) the patient had received deoxycholate or other formulation of amphotericin B within one week prior to study entry; (2) there was clinical and laboratory evidence of veno-occlusive disease in PSCT recipients with no evidence of reversal; (3) patient had moderate or severe liver disease, as defined by AST or ALT > 10 times upper limit of normal (ULN), or total bilirubin > five times ULN, or serum alkaline phosphatase > 10 times ULN; (4) serum creatinine > 2 times ULN; (5) hypokalemia < 3.0 mEq/L; (6) a history of anaphylaxis attributed to amphotericin B; and (7) receipt of other systemically administered antifungal agents.
	The protocol was designed as an open label, sequential dose escalation, multi-dose pharmacokinetic study whichthat enrolled eight patients per each of the four dosage cohorts.  Dosages of 2.5 mg/kg, 5.0 mg/kg, 7.5 mg/kg or 10 mg/kg of L-AMB were administered once daily as a one hour infusion to eight patients in each dosage cohort. Escalation and enrollment into the next dosage cohort was permitted only after evaluation of the safety and tolerability of the patient group receiving the lower dosage.  Administration was continued for a period of at least three days and was discontinued upon recovery from neutropenia (neutrophil counts > 250/L). Patients were permitted to re-enroll into the trial only after a minimum washout period of one month.

Pharmacokinetic sampling.  Two milliliter venous blood samples were centrifuged and the serum fraction stored at -70°C until analysis. First dose pharmacokinetic sample collection times were as follows: prior to dose, at 1 hr (end of infusion), and at 1.5, 2.0, 3, 4, 6, 8, 12, 18 and 24 hours. Twice a week trough samples immediately prior to the next dose were subsequently obtained during daily administration.  Last-dose pharmacokinetic sample time points were then obtained prior to dose, at 1 hr (end of infusion), at 1.5, 2.0, 3, 4, 6, 8, 12, 18, and 24 hours, followed by wash-out samples 2, 3 and 4 (± 24 hours) days after the last dose of L-AMB.

Analytical methods.  Concentrations of amphotericin B in serum were determined by HPLC assay [3]. Following methanol deproteinization, amphotericin B and the internal standard, 3-nitrophenol, were separated by reversed-phase chromatography and detected by UV absorbance at 406 nm. Two overlapping standard curves were used: 0.05 – 20 g/ml, and 0.5 – 200 g/ml. The unweighted correlation coefficient for this assay respectively was 0.998 for both curves with an interday and intraday CV of 1.8 – 11.2% and 6.9 – 10.1%. .

Pharmacokinetic calculations.  The pharmacokinetic profile of amphotericin B following L-AMB administration was determined by noncompartmental analysis. Cmax was determined as the maximum concentration of L-AMB measured.  The terminal elimination half-life (t1/2) was obtained from data in the post distribution phase.  The elimination rate constant ß was defined as 0.693/t1/2.  The area under the concentration versus time curve from time zero to 24 hours (AUC0-24) was calculated using the linear trapezoidal method.  The AUCinf was determined by AUC24 + AUCt-inf with AUCt-inf extrapolated from Ctß, where Ct was the last measured concentration. Total body clearance (Cl) was calculated as Dose/AUCinf. The volume of distribution (V) was calculated as: V=Cl/ß.

Monitoring of safety and tolerability.  The following laboratory examinations were performed on days 3, 5, 7 and twice weekly while on study drug and on the last day of dosing: hemoglobin, hematocrit, total white blood cell count with differential, platelet count, BUN, serum creatinine, calcium, potassium, sodium, AST, ALT, alkaline phosphatase, total bilirubin, magnesium, phosphorus, glucose, and complete urinalysis.  Lipase, amylase, and cholesterol were measured on day 7 weekly and on last day of study drug.  Serum creatinine was performed using the Jaffe method of analysis.
	Infusion-related toxicity was monitored prospectively for each infusion of study drug.  Patients were not premedicated with acetaminophen, diphenhydramine, meperidine or hydrocortisone for the administration of the first dose of L-AMB, thus permitting evaluation of infusion-related toxicity.  If infusion-related symptoms developed during that first infusion, one or more of the aforementioned agents could be administered.  A bedside data extraction sheet was utilized by the nursing staff to record serial vital signs during and after infusion, as well as signs and symptoms of infusion-related toxicity. This data extraction sheet then became a source document for reporting infusion-related toxicity. Vital signs were monitored immediately before, at 5, 10 15, 30 minutes into the infusion and end of the infusion and 30 and 60 minutes post-infusion the first day.  On subsequent infusions, vital signs were obtained pre-infusion, 15 and 30 minutes into the infusion, end of infusion, and 30 and 60 minutes post-infusion. Between doses, vital signs were obtained every four hours. Signs, symptoms, and reported side effects associated with study drug infusion or occurring at any time during the study period were recorded and assessed for relationship to study drug. The relationship of study drug to possible clinical infusion-related toxicity was assessed by each patient’s primary physician.
	Data for safety and tolerability were carefully assessed before escalation to the next dosage cohort. Six of eight patients were required to complete therapy with no significant drug-related grade 3 or grade 4 toxicity according to the NCI Common Toxicity Criteria (http://ctep.info.nih.gov/ctc3/ctc.htm).  Escalation to the next higher dosage level was permitted after mutual agreement between the investigator and the clinical monitor that safety criteria had been fulfilled.  

Pharmacokinetic sampling.  Two milliliter venous blood samples were centrifuged and the serum fraction stored at -70°C until analysis. First dose pharmacokinetic sample collection times were as follows: prior to dose, at 1 hr (end of infusion), and at 1.5, 2.0, 3, 4, 6, 8, 12, 18 and 24 hours. Twice a week trough samples immediately prior to the next dose were subsequently obtained during daily administration.  Last-dose pharmacokinetic sample time points were then obtained prior to dose, at 1 hr (end of infusion), at 1.5, 2.0, 3, 4, 6, 8, 12, 18, and 24 hours, followed by wash-out samples 2, 3 and 4 (± 24 hours) days after the last dose of L-AMB.

Analytical methods.  Concentrations of amphotericin B in serum were determined by HPLC assay [3]. Following methanol deproteinization, amphotericin B and the internal standard, 3-nitrophenol, were separated by reversed-phase chromatography and detected by UV absorbance at 406 nm. Two overlapping standard curves were used: 0.05 – 20 g/ml, and 0.5 – 200 g/ml. The unweighted correlation coefficient for this assay respectively was 0.998 for both curves with an interday and intraday CV of 1.8 – 11.2% and 6.9 – 10.1%. .

Pharmacokinetic calculations.  The pharmacokinetic profile of amphotericin B following L-AMB administration was determined by noncompartmental analysis. Cmax was determined as the maximum concentration of L-AMB measured.  The terminal elimination half-life (t1/2) was obtained from data in the post distribution phase.  The elimination rate constant ß was defined as 0.693/t1/2.  The area under the concentration versus time curve from time zero to 24 hours (AUC0-24) was calculated using the linear trapezoidal method.  The AUCinf was determined by AUC24 + AUCt-inf with AUCt-inf extrapolated from Ctß, where Ct was the last measured concentration. Total body clearance (Cl) was calculated as Dose/AUCinf. The volume of distribution (V) was calculated as: V=Cl/ß.  


Monitoring of efficacy.  This study was not designed for assessment of efficacy.  Nonetheless, patients with documented infections known at baseline were evaluated for response to antifungal therapy as a secondary objective of the clinical trial.  Serial blood cultures, urine cultures, and chest radiographs were performed in all febrile neutropenic patients as appropriate. Computerized tomographic scans and bronchoalveolar lavage were performed as appropriate in evaluating patients for suspected invasive fungal infection.  The response of patients with documented baseline infection was assessed by the investigator using clinical, radiological, and microbiological criteria for complete response, partial response, stabilization, or failure.  For patients enrolled for empirical therapy, success was defined as complete response (resolution of fever and clinical signs and symptoms) or partial response (improvement but not complete resolution of clinical signs and symptoms); failure of empirical therapy was defined as death, breakthrough fungal infection, or withdrawal due to an adverse event.  

Statistical analysis. Comparisons of the mean pharmacokinetic values between different dosage levels of L-AMB were performed by analysis of variance (ANOVA) with Dunnett’s correction for multiple comparisons.  Differences in mean clinical laboratory values and indicators of tolerability to study drug were analyzed by Wilcoxon-rank sum test.  Analysis of dichotomous variables of adverse events and infusion-related reactions were analyzed by Fisher’s exact test.  A value of p 0.05 was considered to indicate a significant difference.Comparisons of the mean pharmacokinetic values between the first versus last doses and between different dosage levels of L-AMB were performed using a two-tailed, unpaired Student’s t-test.  Differences in clinical laboratory values and indicators of tolerability to study drug were analyzed by Wilcoxon-rank sum test (InStat, GraphPad Software, Inc.).  A value of p  0.05 was considered to indicate a significant difference.

RESULTS
Study patient demographics.  A total of 40 patients, with 47 enrollments onto study, received at least one dose of L-AMB (Table 1). Five patients were enrolled more than one time. Thirty-six patient enrollees received at least three doses of L-AMB. These patient enrollees (32 males, 15 females) had a mean age of 7.8 years. Underlying conditions included antineoplastic chemotherapy (31), allogeneic PSCT (10), HIV infection (4), aplastic anemia (1), and chronic granulomatous disease (1). 

Safety.  All but three patients experienced at least one adverse event during the study (Table 2).  No consistent dosage-related trend in most adverse events was observed.  However, at the higher dosage level of 10 mg/kg, there was a trend toward greater hypokalemia and vomiting.
The differences in serum creatinine at baseline and end of therapy by dosage cohort are summarized in Table 3.  Patients in the 5.0 mg/kg and 10 mg/kg cohorts had significant increases in mean serum creatinine during the course of antifungal therapy.  When the changes from baseline to end of therapy are analyzed for all patients, serum creatinine increased from 0.45 ± 0.04 mg/dL to 0.63 ± 0.06 mg/dl (p=0.003).  
The changes of serum creatinine at baseline and end of therapy in individual patients are depicted in Figure 1.  There was no consistent pattern between dosage cohort and the number of patients with an increase in serum creatinine or in the magnitude of change of serum creatinine in individual subjects.  These findings suggest that considerable inter-patient variation occurred in the predilection to LAMB-related nephrotoxicity.
Two patients were withdrawn from study for laboratory abnormalities. One patient had an elevated serum creatinine and another patient had an increase in hepatic transaminases; both patients were enrolled in the 5 mg/kg dosage cohort.  Study drug was discontinued in the former patient because of a rapid rise in serum creatinine, which increased fro 0.5 mg/dl on day 22 to 1.7 mg/dl on day 26.

Tolerability.  All infusions of L-AMB were directly monitored; vital signs, and symptoms were recorded in a data collection sheet at the patient’s bedside.  There was no consistent dose-related trend observed with respect to the overall frequency of IRRs (Table 4).  Three (25%) of 12 patients reported chills/rigors and vomiting in the 10 mg/kg dosage cohort.  Chills and/or rigors were present during 5 (11%) of day 1 infusions.  Among the IRRs, a cluster of symptoms including facial flushing, pruritus, dyspnea, chest pain, and abdominal pains occurred in 10 episodes, suggesting a histamine-mediated reaction.  In addition, musculoskeletal symptoms such as myalgias and arthralgias also were reported. 
There were 63 episodes of IRRs (11%) among the 565 infusions of L-AMB.  Eighteen patients received treatment for infusion-related side effects. Five patients discontinued study drug due to IRRs.  There was no relation among dosage group, frequency of IRR, or discontinuation due to IRR. 

Pharmacokinetics.  The amphotericin B pharmacokinetic parameters calculated using noncompartmental analysis are summarized in Tables 5 and 6 for first and last days, respectively.  The concentration-time curves for the first and last day pharmacokinetics are presented in figures 2 and 3.  There was a high degree of inter-patient variability in pharmacokinetic parameters for first and last days.  The mean AUCinf values on day 1 were higher than anticipated for the 5 and 10 mg/kg dosages and lower than expected for the 7.5 mg/kg dosage, assuming linear dispositionconsistent with nonlinear pharmacokinetics (Figure 2).  The mean AUCinf values on the last day of infusion were higher than expected for the 5 mg/kg dosage and lower than anticipated for the 7.5 mg/kg and 10 mg/kg dosages (Figure 3).  Similar trends were observed for Cmax for the 5.0 mg/kg dosage and the 7.5 mg/kg dosages.  The mean AUCinf for each dosage cohort tended to increase between the first day and last day.   
The mean Cl appeared to increase with increasing dosage on both the first and last days with exception of 10 mg/kg on the first day.  Clearance was consistently diminished after multiple dosing when compared between the first and last days in all dosage cohorts, suggesting a saturable process.  Volume of distribution was determined to be < 1.0 L/kg for most dosages on the first and last days.  

Outcome and Efficacy. Measures of overall antifungal efficacy and outcome by dosage cohort are presented in Table 7.  Twenty-seven (75%) of the 36 enrollments in which patients received at least three doses of study drug were considered to have a successful outcome for empirical therapy or for treatment of documented infection.  Fourteen (39%) of these 36 enrollments resulted in complete resolution of all signs and symptoms. 
	Two patients on the 2.5 mg/kg dosage level developed breakthrough infections (pulmonary aspergillosis and positive blood culture for C. parapsilosis). Three failures were observed in the 5 mg/kg dosage group. One patient died from graft versus host disease, increased creatinine and rash. A patient with chronic granulomatous disease developed pneumonia due to a filamentous fungal pathogen.  A PSCT recipient discontinued therapy secondary to radiological progression of suspected invasive aspergillosis. Two patients at the 7.5 mg/kg dose level were considered to be outcome failures. One patient developed hyperbilirubinemia and a patient with Wiskott-Aldrich syndrome and non-Hodgkin’s lymphoma had pulmonary aspergillosis diagnosed after 30 days of therapy.  There were no outcome failures in the 10 mg/kg cohort; however, there also was no trend of a dose-response relationship in efficacy. 
	Survival within the first 4 days post-treatment was 88% (35/40 patients; 89% 42/47 enrollments).  Survival within 2 months post-treatment was 75% (30/40 patients; 79% 37/47 enrollments). There was no consistent dose-related trend of survival.

DISCUSSION

This prospective trial of the safety, tolerability, and plasma pharmacokinetics of L-AMB in pediatric patients found no dose-limiting toxicity in the four dosage groups from 2.5 mg/kg/day to 10 mg/kg/day.  At the higher dosage level of 7.5-10 mg/kg, there was a trend toward greater hypokalemia and azotemia, as well as in infusion-related dyspnea, vomiting, chills, and rigors.  The pharmacokinetic parameters in pediatric patients were similar to those of adults indicating that based upon these data no dosage adjustment for L-AMB is indicated in pediatric patients. Although the study was not designed to assess efficacy, there was no significant dose-response relationship with therapeutic outcome.  
The trend in AUCs indicates a pattern of high inter-patient variability similar to that of adults in two previous clinical trials.  The first trial studied dosages of 1.0 to 7.5 mg/kg [17] and the second trial studied dosages of 7.5 to 15 mg/kg [18]. The trends of AUC versus dosage bore some similarity to those of adults  but were also distinctive.  For example, the mean AUC0- for 10 mg/kg on the last day was approximately 2.5 times that of the AUC0- for 2.5 mg/kg, while one would anticipate a four-fold difference. 
	While wide interpatient variability is the most plausible explanation for these observations, other possible mechanisms may be hypothesized. One possible mechanism may be induction of clearance by the reticuloendothelial system or other clearance systems at dosages greater than that of 5.0 mg/kg in pediatric patients.  Amphotericin B and L-AMB are removed from the central compartment by the RES.  Increasing concentrations of L-AMB may induce a concentration-dependent mechanism for enhanced clearance of amphotericin B, as observed for the reticuloendothelial elimination of hemoglobin [19], amphotericin B lipid complex [20], or for the renal clearance of carprofen [21].   These clearance mechanisms for L-AMB may be based upon the induction of low-affinity receptors for lipoproteins expressed on the RES. 
This effect of declining AUC at higher dosages is also reflected in comparison of AUCs between those in pediatric and adult patients.  A comparison of L-AMB exposures between pediatric patients in this study and adult patients [18] for mean last day values of AUC0-24 and AUC0- reveal compatible exposures at 2.5, 5.0, and 7.5 mg/kg/day.  The differences in mean last day values of AUC0-24 and AUC0- for 10 mg/kg/day being higher in adults than in pediatric patients may be related to interpatient variability.  A population pharmacokinetic model, which was developed from these data, demonstrated nonlinear pharmacokinetics, as well as a time dependent change that was not explained by any of the covariates monitored in this study [19].
Among the few other studies that have reported circulating concentrations or pharmacokinetics of L-AMB in children, Mehta and colleagues [9] studied the pharmacokinetics of 10 mg/kg once weekly L-AMB in 14 pediatric patients undergoing hematopoietic stem cell transplant.  Unfortunately, as these concentrations are expressed in non-lipid complexed amphotericin B, a comparison of results is not feasible.    Similarly, the study of Kotwani et al studied only one dosage level at 1.0 mg/kg over 28 days in adults, children, and neonates [202].  This study suggested that neonates may have a larger volume of distribution than those of adults.  Hong and colleagues reported a population pharmacokinetic model of L-AMB in pediatric patients with malignant diseases receiving dosages ranging from 0.8 to 5.9 mg/kg/day [213].].  
	The therapeutic implications of dose-dependent plasma exposure in children warrant further study.  Indeed, these findings are compatible with the adult study, which demonstrated no apparent benefit in therapeutic outcome toward higher dosages exceeding 7.5 mg/kg [18], as well as with the recent “AmBiload” study of invasive aspergillosis in adults [7].  In that study, Cornely and colleagues demonstrated that higher dosages of L-AMB did not result in a greater response rate in a prospective randomized trial of L-AMB comparing dosages of 3.0 mg/kg versus 10 mg/kg per day for primary treatment of proven and probable invasive aspergillosis in 201 patients.  This study found similar survival rates and overall response rates in both dosage groups, but a greater frequency of toxicity in the higher dosage group.  
	Among the toxicity profiles seen in this study, there were infusion-related and non-infusion-related adverse events, as have been reported in case reports and case series [11, 17, 224-2729].  Although the number of patients with overall IRRs was similar in each dosage group (4 to 6 per patient), there was a trend of some IRRs (chills/rigors, vomiting, and dyspnea) to occur in the higher dosage groups of 7.5 to 10.0 mg/kg.  Five patients also displayed features of the acute infusion-related reaction complex previously described in adults and adolescents [279], which led to discontinuation.  Each of these events occurred in the higher dosage levels of 7.5 and 10 mg/kg/day.  Among the five patients with acute infusion related reactions (AIRRS), two had dyspnea only, a third had dyspnea plus abdominal pain, a fourth had dyspnea, facial flushing, nausea, and vomiting, and the fifth patient had dsypnea, lip swelling, and facial flushing.  Although these events occurred in the higher dosage group, the AIRRS began early into infusion and the absolute amount of L-AMB infused was relatively small (6 mg to <50 mg).  The possible mechanism for these events may be related to liposomal activation of the C5a component of the complement cascade with ensuing histamine release, as previously described [2830]. 
	While pediatric patients are better able to resist the clinically overt nephrotoxicity of amphotericin B, renal impairment remains a dose limiting toxicity in this population [11].  The mean serum creatinine in three of the four dosage groups increased by approximately 60 to 90% from baseline (Table 4).  In understanding the reason for no appreciable change in mean serum creatinine in the 7.5 mg/kg dosage cohort, this group of patients had a higher pre-existing elevated mean baseline serum creatinine (0.64 mg/dl) versus the other three dosage cohorts (mean baseline serum creatinine 0.33 to 0.44 mg/dl).  Even at dosages of 10 mg/kg, the nephrotoxic adverse effects of L-AMB were well tolerated in most patients.  
There are several possible mechanisms for renal protection of L-AMB and other lipid formulations of amphotericin B [302]: reduced induction of tubuloglomerular feedback [313], high affinity binding to high-density lipoproteins with decreased renal accumulation [324, 335], selective cytotoxicity to fungal versus mammalian cells [346, 357], reduced toxicity to renal vascular endothelial cell membrane [368], and organism-mediated phospholipase-induced release of amphotericin B from lipid formulations [379].   Nevertheless a 7-year-old HIV-infected patient with relapsed cryptococcal meningitis after three weeks of L-AMB 5mg/kg sustained a precipitous rise in serum creatinine from 0.5 to 1.7 mg/dl over four days, necessitating withdrawal from the study.  While double blind randomized trials demonstrate that administration of L-AMB is significantly less nephrotoxic than conventional deoxycholate amphotericin B [11, 15], close monitoring of renal function of pediatric patients receiving L-AMB is certainly warranted.    
	The efficacy of L-AMB has been reported in pediatric patients with a variety of invasive fungal infections [10, 3840-447]. Although this phase I-II study was not powered to determine therapeutic outcome, several observations bear note.  All dosages of L-AMB in this study conferred therapeutic response in some patients.  There was no significant relationship between dosage and frequency of breakthrough invasive fungal infections.  Therapeutic responses to baseline invasive fungal infections also did not correlate with response. These findings are compatible with those of the adult studies, which did not demonstrate a dose-response relationship from 3 mg/kg/d to 10 mg/kg/d for candidiasis and aspergillosis [7, 18].   For other organisms, such as the Mucorlaes, which have higher minimum inhibitory concentrations, dosages of 5-10 mg/kg/d may be more effective [456].  
Peak serum level (Cmax) to the MIC ratio (Cmax/MIC) is the parameter that is predictive of outcome in experimental murine candidiasis for deoxycholate amphotericin B (DAmB).  A Cmax/MIC ratio 5 to 10 results in >103-fold reduction in CFU/g of residual fungal burden in kidneys [46].  Assuming an approximate 5-fold difference in potency between LAmB and DAmB against invasive candidiasis, the Cmax/MIC ratio for LAmB would be 25 to 50.  Given an MIC of 0.25 µg/ml for Candida albicans, the Cmax needed to attain the target ratio is 10 to 20 µg/ml [47].  The data from this study indicate that all studied dosages from 2.5 mg/kg to 10 mg/kg would yield mean Cmax values that would achieve the target Cmax/MIC ratio between 25 and 50.  
There are several limitations of this clinical trial.  Among these are different numbers of patients with data for the first dose versus the last dose within a given dosage cohort.  This reflects the practical limitations of patients being discharged before the last day of pharmacokinetics can be obtained.  Yet another limitation is the variation in duration of antifungal therapy.  This variation is understood as a reflection of the different durations of antifungal therapy needed for the management of each patient.  Of 
	In summary, this study documents the safety, tolerability, and pharmacokinetics of L-AMB in immunocompromised pediatric patients.  Infusion-related toxicity, while uncommon, may require discontinuation. The overall relationship between dosage and exposure was similar between children and adults; however, the wide inter-patient variability warrants further assessment with population-based pharmacokinetic modeling. 
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FIGURE LEGENDS
Figure 1.  Changes in serum creatinine in individual pediatric patients receiving liposomal amphotericin B at 2.5, 5.0, 7.5, and 10.0 mg/kg/day.  Arrows indicate the direction of change of serum creatinine from baseline to end of therapy.  The origin of the arrow indicates the serum creatinine value at baseline, while the tip of the arrow indicates the serum creatinine value at end of therapy.  Those patients with no change in serum creatinine between baseline and end of therapy are designated by .

Figure 2.  Concentration-time curves of liposomal amphotericin B in pediatric patients receiving 2.5 mg/kg (), 5.0 mg/kg (), 7.5 mg/kg (), and 10.0 mg/kg () on day 1 of infusion.  

Figure 3.  Concentration-time curves of liposomal amphotericin B in pediatric patients receiving 2.5 mg/kg (), 5.0 mg/kg (), 7.5 mg/kg (), and 10.0 mg/kg () on last day of infusion.
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